|
Volume
8 Number 9
September 2020
|
|
Home
>
Disciplines
>
Publications
>
Prostate
Cancer Reviews >
Volume
8, Year 2020 >
Number 9, September
|
|
|
Contents
|
▼
|
|
Case
reports
|
|
Diagnosis,
presentation
|
|
Epidemiology,
risk factors, prevention
|
|
Etiology,
pathogenesis, pathology
|
|
Follow-up,
side effects, quality of life
|
|
Integrative
medicine
|
|
Overall
management
|
|
Prognosis,
outcomes
|
|
Treatment
|
|
|
Case
reports
|
▲
|
|
Purohit
S, Bhaladhare S, Marathe N, Shah S, Raj A.
Small
Cell Prostate Cancer with Atypical Presentation -A Case Report and
Review of Literature.
J
Orthop Case Rep.
2020;10(2):50-53. doi: 10.13107/jocr.2020.v10.i02.1692?. Case
report & Review. _
|
|
|
Diagnosis,
presentation
|
▲
|
|
Bauman
GS, Jani AB.
American
Society for Radiation Oncology Editorial: Rapidly Evolving
Technologies Related to Imaging Strategies for Advanced Prostate
Cancer.
Pract
Radiat Oncol.
2020 Sep 2. 2020:S1879-8500(20)30166-1. doi:
10.1016/j.prro.2020.06.009. Editorial;
_
|
|
|
|
Becerra
MF, Alameddine M, Zucker I, Tamariz L, Palacio A, Nemeth Z,
Velasquez MC, Savio LF, Panizzutti M, Jue JS, Soodana-Prakash N,
Ritch CR, Gonzalgo ML, Parekh DJ, Punnen S.
Performance
of Multiparametric MRI of the Prostate in Biopsy Naïve Men: A
Meta-analysis of Prospective Studies.
Urology.
2020 Sep 1. 2020;S0090-4295(20)31039-6. doi:
10.1016/j.urology.2020.06.102. Meta-analysis. _
|
|
|
*
|
Crocerossa
F, Marchioni M, Novara G, Carbonara U, Ferro M, Russo GI,
Porpiglia F, Di Nicola M, Damiano R, Autorino R, Cantiello
F.
Detection
Rate of Prostate-Specific Membrane Antigen Tracers for Positron
Emission Tomography/Computed Tomography in Prostate Cancer
Biochemical Recurrence: A Systematic Review and Network
Meta-Analysis.
J
Urol.
2020 Sep 16. 2020;101097JU0000000000001369. doi:
10.1097/JU.0000000000001369. Review &
Meta-analysis;
_
|
|
|
|
Diao
W, Cao Y, Su D, Jia Z.
Impact
of 68Gallium
prostate-specific membrane antigen tracers on the management of
patients with prostate cancer who experience biochemical
recurrence.
BJU
Int.
2020 Sep 26. doi: 10.1111/bju.15257. Review
& Meta-analysis.
_
|
|
|
|
Evangelista
L, Zattoni F, Cassarino G, Artioli P, Cecchin D, Dal Moro F,
Zucchetta P.
PET/MRI
in prostate cancer: a systematic review and meta-analysis.
Eur
J Nucl Med Mol Imaging.
2020 Sep 8. doi: 10.1007/s00259-020-05025-0. Review
& Meta-analysis.
_
|
|
|
|
Frantzi
M, Hupe MC, Merseburger AS, Schanstra JP, Mischak H, Latosinska A.
Omics
Derived Biomarkers and Novel Drug Targets for Improved
Intervention in Advanced Prostate Cancer.
Diagnostics
(Basel).
2020 Aug 31. 2020;10(9):658. doi: 10.3390/diagnostics10090658.
Review. _
|
|
|
|
French
WW, Wallen EM.
Advances
in the Diagnostic Options for Prostate Cancer.
Postgrad
Med.
2020 Sep 8. doi: 10.1080/00325481.2020.1822067. Review. _
|
|
|
|
Gillies
RJ, Schabath MB.
Radiomics
Improves Cancer Screening and Early Detection.
Cancer
Epidemiol Biomarkers Prev.
2020 Sep 11. 2020;cebp.0075.2020. doi:
10.1158/1055-9965.EPI-20-0075. Review.
_
|
|
|
|
Hadaschik
BA, Giesel FL, Chi K.
Prostate-specific
Membrane Antigen Imaging and Theranostics Impact Patient Outcomes.
Eur
Urol Focus.
2020 Sep 21. 2020;S2405-4569(20)30264-9. doi:
10.1016/j.euf.2020.09.005. Opinion. _
|
|
|
|
Hettiarachchi
D, Geraghty R, Rice P, Sachdeva A, Nambiar A, Johnson M, Gujadhur
R, Mcneill M, Haslam P, Soomro N, Zeeshan Hameed BM, Somani B,
Veeratterapillay R, Rai BP.
Can
the Use of Serial Multiparametric Magnetic Resonance Imaging
During Active Surveillance of Prostate Cancer Avoid the Need for
Prostate Biopsies?-A Systematic Diagnostic Test Accuracy Review.
Eur
Urol Oncol.
2020 Sep 21. 2020:S2588-9311(20)30143-7. doi:
10.1016/j.euo.2020.09.002. Review. _
|
|
|
|
Piccardo
A, Ugolini M, Righi S, Bottoni G, Cistaro A, Paparo F, Giovanella
L, Evangelista L.
Copper,
PET/CT and prostate cancer. A systematic review of the literature.
Q
J Nucl Med Mol Imaging.
2020 Sep 9. doi: 10.23736/S1824-4785.20.03277-X. Review;
_
|
|
|
|
Shaikh
F, Dupont-Roettger D, Dehmeshki J, Kubassova O, Quraishi
MI.
Advanced
Imaging of Biochemical Recurrent Prostate Cancer With PET, MRI,
and Radiomics.
Front
Oncol.
2020 Aug 19. 2020;10:1359. doi: 10.3389/fonc.2020.01359. Opinion.
_
|
|
|
|
Shaish
H.
Structured prostate MRI reporting: how and why.
Abdom
Radiol
(NY).
2020 Sep 12. doi: 10.1007/s00261-020-02720-2. Review.
_
|
|
|
|
Sharma
U, Jagannathan NR.
Metabolism
of prostate cancer by magnetic resonance spectroscopy (MRS).
Biophys
Rev.
2020 Sep 12. 2020;12(5):1163-1173. doi:
10.1007/s12551-020-00758-6. Review.
_
|
|
|
|
Sugano
D, Sanford D, Abreu A, Duddalwar V, Gill I, Cacciamani GE.
Impact
of radiomics on prostate cancer detection: a systematic review of
clinical applications.
Curr
Opin Urol.
2020 Nov;30(6):754-781. doi: 10.1097/MOU.0000000000000822. Review.
_
|
|
|
|
Tucker
D, Zheng W, Zhang DH, Dong X.
Circular RNA and its potential
as prostate cancer biomarkers.
World
J Clin Oncol.
2020 Aug 24. 2020;11(8):563-572. doi: 10.5306/wjco.v11.i8.563.
Review. _
|
|
|
|
Uhr
A, Glick L, Gomella LG.
An
overview of biomarkers in the diagnosis and management of prostate
cancer.
Can
J Urol.
2020 Aug;27(S3):24-27. Review. _
|
|
|
|
Wang
S, Frisbie J, Keepers Z, Bolten Z, Hevaganinge A, Boctor E,
Leonard S, Tokuda J, Krieger A, Siddiqui MM.
The
Use of Three-dimensional Visualization Techniques for Prostate
Procedures: A Systematic Review.
Eur
Urol Focus.
2020 Aug 29. 2020;S2405-4569(20)30215-7. doi:
10.1016/j.euf.2020.08.002. Review.
_
|
|
|
|
Wang
Z, Wang X, Wang WD, Zheng GY, Guo H, Zhang YS.
Value
of Preoperative Neutrophil-to-Lymphocyte Ratio in Predicting
Prognosis of Surgically Resectable Urinary Cancers: Systematic
Review and Meta-Analysis.
Chin
Med Sci J.
2020 Jul 2. 2020;35(3):262-271. doi: 10.24920/003668?. Review &
Meta-analysis. _
|
|
|
|
Yang
L, Tan Y, Dan H, Hu L, Zhang J.
Diagnostic
performance of diffusion-weighted imaging combined with dynamic
contrast-enhanced magnetic resonance imaging for prostate cancer:
a systematic review and meta-analysis.
Acta
Radiol.
2020 Sep 9. 2020;284185120956269. doi: 10.1177/0284185120956269.
Review & Meta-analysis. _
|
|
|
Epidemiology,
risk factors, prevention
|
▲
|
|
Takeshima
Y, Suzuki M, Miyakawa J, Tsuru I, Yamada Y, Nakamura M, Sato Y,
Kawai T, Yamada D, Morikawa T, Kume H.
Latent
prostate cancer among Japanese males: a bibliometric study of
autopsy reports from 1980-2016.
Jpn
J Clin Oncol.
2020 Sep 2. 2020;hyaa161. doi: 10.1093/jjco/hyaa161. Bibliometric
study. _
|
|
|
Etiology,
pathogenesis, pathology
|
▲
|
|
Carpenter
VJ, Patel BB, Autorino R, Smith SC, Gewirtz DA, Saleh
T.
Senescence
and castration resistance in prostate cancer: A review of
experimental evidence and clinical implications.
Biochim
Biophys Acta Rev Cancer.
2020 Sep 18. 2020;1874(2):188424. doi:
10.1016/j.bbcan.2020.188424. Review. _
|
|
|
|
Cimadamore
A, Cheng L, Lopez-Beltran A, Mazzucchelli R, Lucianò
R,
Scarpelli M, Montorsi F, Montironi R.
Added
Clinical Value of Whole-mount Histopathology of Radical
Prostatectomy Specimens: A Collaborative Review.
Eur
Urol Oncol.
2020 Aug 31. 2020;S2588-9311(20)30127-9. doi:
10.1016/j.euo.2020.08.003. Review.
_
|
|
|
|
Katongole
P, Sande OJ, Joloba M, Reynolds SJ, Niyonzima N.
The
human microbiome and its link in prostate cancer risk and
pathogenesis.
Infect
Agent Cancer.
2020 Aug 31. 2020;15:53. doi: 10.1186/s13027-020-00319-2. Review.
_
|
|
|
|
Messina
C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, Olmos D,
Boccardo F, Zanardi E.
BRCA
Mutations in Prostate Cancer: Prognostic and Predictive
Implications.
J
Oncol.
2020 Sep 7. 2020;2020:4986365. doi: 10.1155/2020/4986365. Review.
_
|
|
|
|
Powell
IJ, Chinni SR, Reddy SS, Zaslavsky A, Gavande N.
Pro-inflammatory
cytokines and chemokines initiate multiple prostate cancer
biologic pathways of cellular proliferation, heterogeneity and
metastasis in a racially diverse population and underlie the
genetic/biologic mechanism of racial disparity: Update.
Urol
Oncol.
2020 Sep 5. 2020:S1078-1439(20)30387-2. doi:
10.1016/j.urolonc.2020.08.019. Review. _
|
|
|
|
Saranyutanon
S, Deshmukh SK, Dasgupta S, Pai S, Singh S, Singh AP.
Cellular
and Molecular Progression of Prostate Cancer: Models for Basic and
Preclinical Research.
Cancers
(Basel).
2020 Sep 17. 2020;12(9):2651. doi: 10.3390/cancers12092651.
Review. _
|
|
|
|
Vellky
JE, Ricke WA.
Development
and prevalence of castration-resistant prostate cancer subtypes.
Neoplasia.
2020 Sep 25. 2020;22(11):566-575. doi: 10.1016/j.neo.2020.09.002.
Review. _
|
|
|
|
Zhang
E, Zhang M, Shi C, Sun L, Shan L, Zhang H, Song Y.
An
overview of advances in multi-omics analysis in prostate cancer.
Life
Sci.
2020 Sep 6. 2020;260:118376. doi: 10.1016/j.lfs.2020.118376.
Review..
_
_
|
|
|
Follow-up,
side effects, quality of life
|
▲
|
|
Brunckhorst
O, Hashemi S, Martin A, George G, Van Hemelrijck M, Dasgupta P,
Stewart R, Ahmed K.
Depression,
anxiety, and suicidality in patients with prostate cancer: a
systematic review and meta-analysis of observational
studies.
Prostate
Cancer Prostatic Dis.
2020 Sep 25. doi: 10.1038/s41391-020-00286-0. Review
& Meta-analysis.
_
|
|
|
|
Higano
CS.
Update
on cardiovascular and metabolic risk profiles of hormonal agents
used in managing advanced prostate cancer.
Urol
Oncol.
2020 Sep 6. 2020:S1078-1439(20)30326-4. doi:
10.1016/j.urolonc.2020.07.004. Review.
_
|
|
|
|
Odeo
S, Degu A.
Factors
affecting health-related quality of life among prostate cancer
patients: A systematic review.
J
Oncol Pharm Pract.
2020 Sep 25. 2020;1078155220959414. doi: 10.1177/1078155220959414.
Review. _
|
|
|
Integrative
medicine
|
▲
|
|
Barbalata
CI, Tefas LR, Achim M, Tomuta I, Porfire AS.
Statins
in risk-reduction and treatment of cancer.
World
J Clin Oncol.
2020 Aug 24. 2020;11(8):573-588. doi: 10.5306/wjco.v11.i8.573.
Review. _
|
|
|
|
Crocetto
F, Boccellino M, Barone B, Di Zazzo E, Sciarra A, Galasso G,
Settembre G, Quagliuolo L, Imbimbo C, Boffo S, Angelillo IF, Di
Domenico M.
The
Crosstalk between Prostate Cancer and Microbiota Inflammation:
Nutraceutical Products Are Useful to Balance This
Interplay?
Nutrients.
2020 Aug 31. 2020;12(9):2648. doi: 10.3390/nu12092648. Review. _
|
|
|
|
Mehrzadi
MH, Hosseinzadeh A, Juybari KB, Mehrzadi S.
Melatonin
and urological cancers: a new therapeutic approach.
Cancer
Cell Int.
2020 Sep 10. 2020;20:444. doi: 10.1186/s12935-020-01531-1. Review.
_
Erratum
in: Cancer
Cell Int.
2020 Sep 28. 2020;20:466. _
.
|
|
|
|
Santucci
C, Gallus S, Martinetti M, La Vecchia C, Bosetti C.
Aspirin
and the risk of nondigestive tract cancers: An updated
meta-analysis to 2019.
Int
J Cancer.
2020 Sep 27. doi: 10.1002/ijc.33311. Meta-analysis. _
|
|
|
|
Singh
K, Jamshidi N, Zomer R, Piva TJ, Mantri N.
Cannabinoids
and Prostate Cancer: A Systematic Review of Animal Studies.
Int
J Mol Sci.
2020 Aug 29. 2020;21(17):6265. doi: 10.3390/ijms21176265. Review.
_
|
|
|
Overall
management
|
▲
|
|
Gilligan
T et al., PDQ Adult Treatment Editorial Board.
Prostate
Cancer Treatment (PDQ®): Health Professional Version.
PDQ
Cancer Inf Summ.
2020 Sep 23. NCBI Bookshelf: NBK66036. Review. _
|
|
|
|
Gutiontov
SI, Pitroda SP, Weichselbaum RR.
Oligometastasis:
Past, Present, Future.
Int
J Radiat Oncol Biol Phys.
2020 Nov 1. 2020;108(3):530-538. doi:
10.1016/j.ijrobp.2020.02.019. Review.
_
|
|
|
|
Lowrance
WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard
DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman
AL, Cookson MS.
Advanced
Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
J
Urol.
2020 Sep 22. 2020;101097JU0000000000001375.
doi: 10.1097/JU.0000000000001375. Guidelines.
_
|
|
|
|
Lowrance
WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard
DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman
AL, Cookson MS.
Advanced
Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
J
Urol.
2020 Sep 22. 2020;101097JU0000000000001376.
doi: 10.1097/JU.0000000000001376. Guidelines.
_
|
|
|
|
Miyahira
AK, Pienta KJ, Babich JW, Bander NH, Calais J, Choyke P, Hofman
MS, Larson SM, Lin FI, Morris MJ, Pomper MG, Sandhu S, Scher HI,
Tagawa ST, Williams S, Soule HR.
Meeting
report from the Prostate Cancer Foundation PSMA theranostics state
of the science meeting.
Prostate.
2020 Aug 31. doi: 10.1002/pros.24056. Meeting report. _
|
|
|
|
Shah
A, Shah AA, K N, Lobo R.
Mechanistic
targets for BPH and prostate cancer-a review.
Rev
Environ Health.
2020 Sep 22. doi: 10.1515/reveh-2020-0051. Review.
_
|
|
|
|
Schuettfort
VM, Pradere B, Rink M, Comperat E, Shariat SF.
Pathomics
in urology.
Curr
Opin Urol.
2020 Nov;30(6):823-831. doi: 10.1097/MOU.0000000000000813. Review.
_
|
|
|
|
Wake
N, Nussbaum JE, Elias MI, Nikas CV, Bjurlin MA.
3D
Printing, Augmented Reality, and Virtual Reality for the
Assessment and Management of Kidney and Prostate Cancer: A
Systematic Review.
Urology.
2020 Jun 11. 2020;143:20-32. doi: 10.1016/j.urology.2020.03.066.
Review.
_
|
|
|
|
Zaorsky
NG, Spratt DE, Kishan AU, Culp SH, Showalter TN.
Editorial:
Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence
and Emerging Options.
Front
Oncol.
2020 Aug 27;10:1616. doi: 10.3389/fonc.2020.01616. Editorial.
_
|
|
|
Prognosis,
outcomes
|
▲
|
|
Saoud
R, Heidar NA, Cimadamore A, Paner GP.
Incorporating
Prognostic Biomarkers into Risk Assessment Models and TNM Staging
for Prostate Cancer.
Cells.
2020 Sep 17. 2020;9(9):2116. doi: 10.3390/cells9092116. Review. _
|
|
|
|
Wright
KM.
Two
Retrospective Analyses Show No Associated Adverse Outcomes With
Delayed RP.
Oncology
(Williston
Park). 2020 Sep 15. 2020;34(9):344-345. doi:
10.46883/ONC.2020.3409.0344. Perspective. _
|
|
|
Treatment
|
▲
|
|
Barani
M, Sabir F, Rahdar A, Arshad R, Kyzas GZ.
Nanotreatment
and Nanodiagnosis of Prostate Cancer: Recent Updates.
Nanomaterials
(Basel).
2020 Aug 28. 2020;10(9):1696. doi: 10.3390/nano10091696. Review. _
|
|
|
|
Connor
MJ, Smith A, Miah S, Shah TT, Winkler M, Khoo V, Ahmed HU.
Targeting
Oligometastasis with Stereotactic Ablative Radiation Therapy or
Surgery in Metastatic Hormone-sensitive Prostate Cancer: A
Systematic Review of Prospective Clinical Trials.
Eur
Urol Oncol.
2020 Sep 3. 2020;3(5):582-593. doi: 10.1016/j.euo.2020.07.004.
Review. _
|
|
|
|
Cuccia
F, Mazzola R, Nicosia L, Giaj-Levra N, Figlia V, Ricchetti F, Rigo
M, Vitale C, Corradini S, Alongi F.
Prostate
re-irradiation: current concerns and future perspectives.
Expert
Rev Anticancer Ther.
2020 Sep 10. 2020;1-10. doi: 10.1080/14737140.2020.1822742.
Review. _
|
|
|
*
|
Dahm
P, Brasure M, Ester E, Linskens EJ, MacDonald R, Nelson VA, Ryan
C, Saha J, Sultan S, Ullman KE, Wilt TJ.
Therapies
for Clinically Localized Prostate Cancer.
AHRQ
Comp Eff Rev.
2020 Sep. Report No.: 20-EHC022. Review.
_
|
|
|
|
Dror
CM, Chi KN.
Apalutamide
for the treatment of metastatic castration-sensitive prostate
cancer.
Future
Oncol.
2020 Sep 4. doi: 10.2217/fon-2020-0557. Review. _
|
|
|
|
Han
HJ, Li YR, Roach M 3rd, Aggarwal R.
Dramatic
response to combination pembrolizumab and radiation in metastatic
castration resistant prostate cancer.
Ther
Adv Med Oncol.
2020 Aug 25. 2020;12:1758835920936084. doi:
10.1177/1758835920936084. Case report & Review. _
|
|
|
|
Handa
S, Hans B, Goel S, Bashorun HO, Dovey Z, Tewari A.
Immunotherapy
in prostate cancer: current state and future perspectives.
Ther
Adv Urol.
2020 Sep 3. 2020;12:1756287220951404. doi:
10.1177/1756287220951404. Review.
_
|
|
|
|
Hoy
SM.
Apalutamide:
A Review in Metastatic Castration-Sensitive Prostate Cancer.
Drugs.
2020 Sep 15. 2020;80(15):1579-1585. doi:
10.1007/s40265-020-01401-0. Review.
_
|
|
|
|
Ihrig
A, Maatouk I, Friederich HC, Baunacke M, Groeben C, Koch R, Thomas
C, Huber J.
The
Treatment Decision-making Preferences of Patients with Prostate
Cancer Should Be Recorded in Research and Clinical Routine: a
Pooled Analysis of Four Survey Studies with 7169 Patients.
J
Cancer Educ.
2020 Sep 17. doi: 10.1007/s13187-020-01867-2. Pooled analysis. _
|
|
|
|
Khera
M.
Controversies
with testosterone therapy.
Can
J Urol.
2020 Aug;27(S3):20-23. Review. _
|
|
|
|
LiverTox:
Clinical and Research Information on Drug-Induced Liver
Injury
Cabazitaxel.
Natl
Inst Diabetes Dig Kidney Dis.
2020 Sep 7. NCBI bookshelf: NBK548533. Review. _
|
|
|
|
Marra
G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, Ploussard
G, van den Bergh RCN, Kretschmer A, Thibault C, Ost P, Tilki D,
Kasivisvanathan V, Moschini M, Sanchez-Salas R, Gontero P, Karnes
RJ, Montorsi F, Gandaglia G; EAU-YAU Prostate Cancer Working
Party.
Management
of Patients with Node-positive Prostate Cancer at Radical
Prostatectomy and Pelvic Lymph Node Dissection: A Systematic
Review.
Eur
Urol Oncol.
2020 Sep 12. 2020;3(5):565-581. doi: 10.1016/j.euo.2020.08.005.
Review. _
|
|
|
|
Mayer
C, Kumar A.
Brachytherapy.
StatPearls
Publ.
2020 Sep 15. NCBI Bookshelf: NBK562190. Review. _
|
|
|
|
Morgans
AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, Sartor
O.
Androgen
receptor inhibitor treatments: Cardiovascular adverse events and
comorbidity considerations in patients with non-metastatic
prostate cancer.
Urol
Oncol.
2020 Sep 18. 2020:S1078-1439(20)30370-7. doi:
10.1016/j.urolonc.2020.08.003. Review.
_
|
|
|
|
Mori
K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E,
Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S,
Shariat SF.
Apalutamide,
enzalutamide, and darolutamide for non-metastatic
castration-resistant prostate cancer: a systematic review and
network meta-analysis.
Int
J Clin Oncol.
2020 Sep 14. 2020;25(11):1892-1900. doi:
10.1007/s10147-020-01777-9. Review
&
Meta-analysis.
_
|
|
|
|
Nizialek
E, Antonarakis ES.
PARP
Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Cancer
Manag Res.
2020 Sep 7. 2020;12:8105-8114. doi: 10.2147/CMAR.S227033. Review.
_
|
|
|
|
Okoye
E, Saikali SW.
Orchiectomy.
StatPearls
Publ.
2020 Sep 3. NCBI Bookshelf: NBK562336. Review. _
|
|
|
|
Royce
TJ, Mavroidis P, Wang K, Falchook AD, Sheets NC, Fuller DB,
Collins SP, El Naqa I, Song DY, Ding GX, Nahum AE, Jackson A,
Grimm J, Yorke E, Chen RC.
Tumor
Control Probability Modeling and Systematic Review of the
Literature of Stereotactic Body Radiation Therapy for Prostate
Cancer.
Int
J Radiat Oncol Biol Phys.
2020 Sep 5. 2020;S0360-3016(20)34102-X. doi:
10.1016/j.ijrobp.2020.08.014. Review.
_
|
|
|
|
Rizzo
A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Giunchi F,
Cheng L, Lopez-Beltran A, Fiorentino M, Montironi R, Massari F.
Is
There a Role for Immunotherapy in Prostate Cancer?
Cells.
2020 Sep 8. 2020;9(9):E2051. doi: 10.3390/cells9092051. Review.
_
|
|
|
|
Satapathy
S, Mittal BR, Sood A.
Visceral
Metastases as Predictors of Response and Survival Outcomes in
Patients of Castration-Resistant Prostate Cancer Treated With
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand
Therapy: A Systematic Review and Meta-analysis.
Clin
Nucl Med.
2020 Sep 15. doi: 10.1097/RLU.0000000000003307. Review &
Meta-analysis;
_
|
|
|
|
Southcott
D, Awan A, Ghate K, Clemons M, Fernandes R.
Practical
update for the use of bone-targeted agents in patients with bone
metastases from metastatic breast cancer or castration-resistant
prostate cancer.
Curr
Oncol.
2020 Aug 1. 2020;27(4):220-224. doi: 10.3747/co.27.6631. Review. _
|
|
|
|
Spratt
DE, Tward JD.
Absolute
versus Relative Benefit of Androgen Deprivation Therapy for
Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize
Therapy.
Int
J Radiat Oncol Biol Phys.
2020 Sep 11. 2020;S0360-3016(20)31252-9. doi:
10.1016/j.ijrobp.2020.06.011. Editorial. _
|
|
|
|
Swerdloff
R, Wang C.
Reflections
on the T Trials.
Andrology.
2020 Sep 9. doi: 10.1111/andr.12901. Review. _
|
|
|
|
Tan
G, Xuan Z, Li Z, Huang S, Chen G, Wu Y, Chen X, Liang Z, Wu A.
The
efficacy and safety of abiraterone acetate in patients with
high-risk prostate cancer: a meta-analysis based on six randomized
control trials.
Transl
Androl Urol.
2020 Aug;9(4):1691-1699. doi: 10.21037/tau-20-1058. Meta-analysis.
_
|
|
|
bottom
|
▲
|
|
|
***********************
|
|
